Navigation Links
Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Date:5/14/2009

LAKE FOREST, Ill., May 14 /PRNewswire/ -- - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced the launch of Enlon(R) (edrophonium chloride injection, USP) and Enlon-Plus(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The acquisition and launch of Enlon(R) represent Bioniche's continued growth and a commitment to bringing this important therapy back to market and into the hands of health care professionals," said Steve Thornton, CEO, Bioniche Pharma.

Bioniche purchased the rights and certain assets related to the Enlon(R) product line from Baxter Corporation, which discontinued Enlon(R) in February 2008. According to IMS data, 2007 sales of Enlon(R) and Enlon-Plus(R) totaled $2,727,000 and 307,000 units.

Bioniche will supply Enlon(R) in 10 mg/mL, 15 mL vials and Enlon-Plus(R) in 15 mL vials, in addition to the currently available 5 mL ampul of Enlon-Plus(R).

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, ... the promotion of two long-standing principal investigators (PI) to the roles of Chief ... and Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
Breaking Biology News(10 mins):